Table 3 Summary of findings
|  | Number of studies | Number of Participants | Mean Age | Weighted Average Final Dose (µg/daily) | Pre-intervention weighted average(SD) | Post-intervention weighted average(SD) | Average Difference % | SMD | SMD Interpretation |
|---|---|---|---|---|---|---|---|---|---|
Spasticity severity, Ashworth Scale | 11 | 186 | 16.00 | 333 | 3.41 (0.79) | 1.98 (0.71) | -41.90% | -1.48 | Very large difference |
Spasticity severity, Modified Ashworth Scale | 8 | 157 | 15.45 | 243 | 2.93 (0.78) | 1.82 (0.74) | -37.95% | -1.78 | Very large difference |
Total | 19 | 343 | 15.78 | 289 | 3.2 (0.78) | 1.91 (0.72) | -40.25% | -1.70 | Very large difference |
Motor function, GMFM score | 6 | 117 | 13.63 | 203 | 40.03 (26.01) | 43.88 (26.18) | 9.62% | 0.15 | Small difference |